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 Abstract 27 
Current anti-osteoporotic pharmacological treatments reduce fracture risk in part by 28 
altering bone remodeling/modeling.  These effects can manifest on any or all of the bone 29 
envelopes – periosetal, intracortical, and trabecular/endocortical – each of which has 30 
unique effects on the biomechanical properties of bone.  The purpose of this review is to 31 
provide an overview of how the most common FDA-approved anti-osteoporosis agents 32 
(bisphosphonates, estrogen/hormone replacement therapy, selective estrogen receptor 33 
modulators (SERMs), and parathyroid hormone (PTH)) affect tissue-level 34 
remodeling/modeling on each of the bone surfaces.  Iliac crest biopsy data, the only 35 
means of assessing surface-specific bone formation in humans, exist for all of these 36 
agents although they predominately focus on trabecular/endocortical surfaces.  Data from 37 
pre-clinical animal models provide an essential complement to human studies, 38 
particuarily for changes on periosteal surfaces and within the intracortical envelope.  39 
Although all of the anti-catabolic agents (estrogen replacement therapy, SERMs, 40 
bisphosphonates) exert positive effects on the various bone surfaces, the bisphosphonates 41 
produce the unique biomechanical combination of allowing normal periosteal expansion 42 
while limiting remodeling-induced bone loss on intracortical and trabecular/endocortical 43 
surfaces.  PTH, the only FDA-approved anabolic agent, exerts biomechanically favorable 44 
alterations though enhanced trabecular/endocortical surface activity while also 45 
stimulating periosetal expansion.  Through understanding how current and future anti-46 
osteoporotic agents influence surface-specific bone activity we will move one step closer 47 
to developing agents that could potentially target a particular bone surface. 48 
Key words:  bisphosphonates, estrogen/hormone replacement therapy, selective estrogen 49 
receptor modulators (SERMs), parathyroid hormone 50 
51 
Introduction 52 
Current osteoporosis pharmacoloical treatments are highly effective in reducing fracture 53 
risk [1-3].  The mechanisms underlying fracture risk reduction with the various 54 
treatments is not completely understood but is due in large part to the effect these agents 55 
have on bone remodeling/modeling.  Bone remodeling, the coupled process of bone 56 
resorption and formation, serves to renew bone tissue and occurs on trabecular and 57 
endocortical bone surfaces and within the cortex (intracortical remodeling) (Fig. 1).  58 
Bone modeling, an uncoupled process in which formation or resorption occur 59 
independent of the other, occurs on trabecular, endocortical, and periosteal surfaces.   60 
 61 
Anti-osteoporotic agents can be classified as anti-catabolic or anabolic [4].  Anti-catablic 62 
agents, including bisphosphonates, estrogen/hormone replacement therapy (HRT), 63 
selective estrogen receptor modulators (SERMs), and calcitonin work primarily by 64 
suppressing bone remodeling.  Remodeling suppression slows bone loss, preserving bone 65 
architecture and geometry.  The only anabolic agent currently approved for treating 66 
osteoporosis, parathyroid hormone (PTH), stimulates both modeling and remodeling 67 
which preserves, and in some cases enhances, bone architecture and geometry.  While the 68 
modeling/remodeling effect of each anti-catabolic and anabolic agent is important, the 69 
surface(s) on which the effects occur are perhaps more important for bone biomechanics 70 
and fracture risk reduction.   71 
 72 
The purpose of this review is toprovide an overview of how the FDA-approved anti-73 
osteoporosis agents affect tissue-level remodeling/modeling on eavh of the bone 74 
envelopes - periosteal, intracortical, and endocortical/trabecular - and how this is likely to 75 
influence bone biomechanics. As a limiated amount of human data exist (from bone 76 
biopsy analyses), the majority of information comes from pre-clinical animal studies.  77 
This results in a certain degree of ambiguity with respect to determining how each agent 78 
affects the various surfaces as differences among studies, such as species, treatment (dose 79 
and duration), and whether or not the animals are intact or ovariectomized, all influence 80 
remodeling/modeling effects.  Therefore, for each of the bone surfaces, the effects of the 81 
various treatments will be summarized for humans, intact animals, and ovariectomized 82 
animals, the latter two catagories focusing mostly on large animal models. 83 
 84 
Periosteal surface 85 
Periosteal bone surfaces primarily undergo modeling which is most prominent during 86 
growth and development yet continues at a slower rate in adults [5].  Remodeling does 87 
occur on periosteal surfaces [6-8] but is generally considered to constitute a small 88 
percentage of overall activity on this surface.  The addition of bone to the periosteal 89 
surface exponentially enhances bone biomechanical properties by increasing the cross-90 
sectional moment of inertia [7, 9].  This is true both for bones made exclusively of 91 
cortical bone (e.g. long bone diaphysis) and for those with significant amounts of 92 
trabecular bone (e.g. vertebra and femoral neck) [10].  The clinical implications of 93 
periosteal expansion are significant as only a small amount of bone needs to be added to 94 
this surface to enhance the biomechanical properties [7, 11].  Periosteal expansion can 95 
also offset the negative biomechanical effects associated with bone loss from other bone 96 
envelopes as only 30% of bone mass lost from the endocortical surface needs to be added 97 
to the periosteal surface to achieve equivalent biomechanical properties [11].   Despite 98 
the substantial biomechanical benefit of periosteal apposition, very little clinical data 99 
exists concerning the effects of anti-osteoporosis pharmaceutical agents on this surface.   100 
 101 
Loss of estrogen increases periosteal expansion while estrogen supplementation 102 
suppresses expansion [12-15].  Ample histological data exist concerning the effects of 103 
hormone/estrogen replacement therapy (HRT) in humans yet they do not routinely 104 
include analyses of the periosteal surface.  The available data, published only in abstract 105 
form, suggest reduced periosteal formation with HRT [16].  There is no data on the 106 
effects of selective estrogen receptor modulators (SERMs) on periosteal bone formation.  107 
Raloxifene, one of the most commonly studied SERMs, had no effect on femoral 108 
periosteal bone formation in ovariectomized cynomolgus monkeys suggesting it does not 109 
inhibit periosteal expansion in estrogen-deplete situations [15].  Conversely, in an intact 110 
beagle dog model where endogenous estrogen levels are normal, raloxifene significantly 111 
enhanced periosteal bone formation rate compared to controls [17].   112 
 113 
Bisphosphonates exert their skeletal effect through suppression of remodeling and 114 
therefore would be expected to have minimal direct effect on periosteal surfaces.  Clinical 115 
data describing bone formation activity on periosteal surfaces, published only in abstract 116 
form, suggest no effect of alendronate on the periosteal surface of iliac crest biopsies [16, 117 
18].  Pre-clinical studies with intact beagles [17, 19-21], ovariectomized beagles [22], and 118 
intact minipigs [23] have consistently shown no significant effect of bisphosphonates on 119 
periosteal bone formation.  Significant suppression of periosteal bone formation has been 120 
shown in several rodent studies [24-26] although the absence of similar data in larger pre-121 
clinical models or humans suggest this may a species-specific effect.  122 
 123 
As an anabolic agent, intermittent PTH (teriparatide, synthetic PTH [hPTH(1-34)], 124 
recombinant human teriparatide [rhPTH(1-34)], or PTH(1-84)), would be expected to 125 
have the greatest effect of all the approved osteoporosis agents on periosteal bone [3, 27].  126 
While iliac crest biopsy samples from PTH-treated patients consistently show increased 127 
cortical thickness compared to placebo-treated patients [28-31], periosteal surface bone 128 
formation results have been conflicting.  Following 1 month of treatment, periosteal bone 129 
formation rate was significantly higher than controls [32] showed no significant 130 
difference between PTH- and placebo-treated patients [28, 33].  Intact rabbits, the only 131 
large animal model in which periosteal bone responses to PTH have been examined, have 132 
shown significantly higher periosteal bone formation with PTH treatment compared to 133 
vehicle [34-36].   134 
 135 
Summary- Periosteal surfaces (Table 1) 136 
Periosteal expansion has a significant effect on fracture risk yet there are minimal data 137 
describing how anti-osteoporosis agents influence activity on this surface.  Beginning at 138 
menopause, the loss of endogenous estrogen simulates periosteal expansion.  139 
Estrogen/hormone replacement therapy suppresses this periosteal expansion while 140 
bisphosphonates have no effect.  The human data concerning SERMs and PTH on 141 
periosteal bone are insufficient to draw conclusions concerning their effects although 142 
some clinical and the majority of pre-clinical data suggest an anabolic effect (or at worst 143 
no effect) with PTH. 144 
 145 
Intracortical envelope  146 
The bone cortex of humans and many large animal research models (non-human 147 
primates, dogs, pigs, rabbits) routinely undergoes intracortical (osteonal) [37, 38].  148 
Similar to trabecular bone remodeling, the loss of estrogen at menopause is associated 149 
with an imbalance in the amount of bone formation relative to resorption within 150 
intracortical remodeling units.  This negative bone balance, coupled with the increases in 151 
intracortical remodeling, result in high levels of cortical porosity in postmenopausal 152 
women.  Intracortical porosity is inversely related to mechanical properties [39, 40] yet 153 
its effect is highly dependent on the spatial location of the pores. In bending or torsion, 154 
cortical porosity near the outer periosteal surface has a greater negative effect on 155 
biomechanics as compared to if the voids are near the endocortical surface [34, 39].  As 156 
with the periosteal surface, few clinical data exist concerning the effects of 157 
pharmaceutical agents on intracortical remodeling emphasizing the importance of pre-158 
clinical models.  In the case of intracortical remodeling, pre-clinical models are limited 159 
exclusively to large animal models as under normal physiological conditions rodents lack 160 
intracortical remodeling.   161 
 162 
Reductions in circulating estrogen increase cortical porosity through stimulation of 163 
intracortical remodeling [15, 22, 41].  In response to drug-induced or naturally occurring 164 
reductions in circulating estrogen, HRT inhibited increased intracortical remodeling and 165 
cortical porosity [41, 42].  Similar results have been noted in non-human primates 166 
wherein intracortical remodeling increased with estrogen withdrawal leading to increases 167 
in cortical porosity [15].  These increases in remodeling and porosity were reduced in 168 
animals treated with either estrogen or raloxifene [15].  Treatment of intact beagles with 169 
raloxifene had no effect on intracortical remodeling [17].   170 
 171 
Bisphosphonates, due to their suppression of remodeling, would be expected to suppress 172 
intracortical remodeling.  Human data are limited and conflicting.  Following 1 to 3 years 173 
of risedronate treatment, iliac crest cortical porosity was not different compared to 174 
baseline levels or age-matched placebo controls [43, 44].  Conversely, biopsies from 175 
women treated for 2-3 years with alendronate had significantly lower cortical porosity in 176 
the iliac crest compared to placebo-treated patients [45].  Pre-clinical models consistently 177 
document reductions in intracortical remodeling with bisphosphonates.  In 178 
ovariectomized non-human primates clodronate suppressed tibia intracortical bone 179 
formation to control levels [46] while ibandronate reduced intracortical remodeling in the 180 
rib and central radius, but not the femoral neck, compared to controls [47].  Suppression 181 
of intracortical turnover with bisphosphonates has also been shown in 182 
ovariohysterectomized beagles [22], intact beagles [19, 21, 48], and intact minipigs [23].   183 
 184 
Of the approved osteoporosis treatments, PTH has the most distinct effect on intracortical 185 
remodeling.  Using intact female rabbits, PTH has been shown to produce a rapid 186 
increase (within the first remodeling cycle) of intracortical bone remodeling [36] which is 187 
sustained with continued treatment [35, 36].  This stimulation of remodeling leads to a 188 
significant increase in cortical porosity [35, 36].  While an increase in porosity would be 189 
predicted to reduce biomechanical properties, the preferential location of intracortical 190 
remodeling and porosity near the endocortical surface with PTH minimized any negative 191 
biomechanical effects.  For example, the increased porosity near the endocortical surface 192 
with PTH compromised the cross-sectional moment of inertial (CSMI; an index of 193 
biomechanical strength) by less than 2%; if this same amount of porosity were located 194 
near the periosteal surface the CSMI would be reduced by almost 10% [35].  Similar 195 
results have been documented in ovariectomized non-human primates where intracortical 196 
turnover rate was significantly increased in the femur [49], humerus [50], and femoral 197 
neck [49] following PTH treatment.  The increased porosity with PTH in these non-198 
human primate studies was most notable near the endocortical surface [50], as with the 199 
rabbits, and therefore resulted in only minimal consequences to the biomechanical 200 
properties of these bones [50].  Increases in cortical porosity with PTH have also been 201 
shown in an intact dog model suggesting that similar changes within the cortex occur 202 
with PTH treatment when estrogen levels are normal [51].  Human data concerning 203 
changes with PTH are limited, yet the porosity data are not consistent with pre-clinical 204 
studies.  Paired iliac crest biopsies from PTH-treated patients showed a trend toward 205 
increased porosity [30] although there was clearly no effect in two other studies of PTH-206 
treatment [28, 29]; these clinical studies did not assess intracortical remodeling. 207 
 208 
Summary- Intracortical envelope (Table 1) 209 
Intracortical remodeling increases during menopause, leading to higher levels of cortical 210 
porosity which reduces biomechanical properties.  Anti-catabolic osteoporosis agents, 211 
HRT, SERMs, and bisphosphonates, appear to suppress intracortical remodeling and 212 
therefore reduce cortical porosity.  Several large animal models show PTH stimulates 213 
intracortical remodeling and increases cortical porosity, the biomechanical consequences 214 
of which are minimized through preferential location of such activity near the 215 
endocortical surface.  Based on these data, the anti-catabolic agents provide the most 216 
favorable effect on intracortical bone as they reduce cortical porosity in postmenopausal 217 
women.  However anabolic agents are also attractive for this bone envelope as enhanced 218 
remodeling would serve to renew bone tissue and occur spatially such that it has minimal 219 
consequences to biomechanics. 220 
 221 
Trabecular/Endocortical surfaces 222 
At menopause, bone remodeling increases on trabecular and endocortical surfaces [52-223 
54] resulting in a significant loss of bone volume and trabecular architecture [44, 55].  224 
Bone formation activity on the trabecular surface is the most studied of the bone 225 
envelopes however it is the most complex surface to assess how remodeling/modeling 226 
influences biomechanics due to the intimate relationship between trabecular and cortical 227 
bone.  There is a clear biomechanical benefit of increasing trabecular bone volume with 228 
the enhancement of trabecular number having a greater benefit compared to increasing 229 
trabecular thickness [56].  Equally important to biomechanics is having a well-connected 230 
trabecular network.  Therefore, changes in both bone volume and architecture likely 231 
determine the ultimate biomechanical effect of anti-osteoporosis treatments on trabecular 232 
bone. 233 
 234 
The effect of HRT on trabecular surface activity is conflicting.  HRT has been shown to 235 
significantly suppress trabecular bone remodeling in the majority of human studies [54, 236 
57-60] although other studies have shown no effect [61-64].  Similar discrepancies exist 237 
for the effects of HRT on bone volume and architecture with one study showing 238 
beneficial effects [62] and others showing no effect [58, 60, 63, 64].  Data from humans 239 
treated with SERMs have provided more consistent results compared to HRT, having 240 
shown significant [54, 65] and non-significant [58] reductions in trabecular bone 241 
remodeling with raloxifene compared to controls.  Ovariectomized non-human primates 242 
had significantly lower trabecular and endocortical bone formation rates at the iliac crest, 243 
vertebra, and tibia when treated with either estrogen or raloxifene [15, 66].  Intact beagle 244 
dogs have non-significantly lower trabecular bone remodeling with raloxifene [67]. 245 
 246 
Studies examining the effect of bisphosphonates on trabecular bone remodeling and bone 247 
volume consistently show significant suppression of bone remodeling on both trabecular 248 
and endocortical surfaces [43, 68-71].  These reductions in remodeling with 249 
bisphosphonate treatment are associated with prevention of the normal loss of bone 250 
volume and architecture in placebo-treated patients [43, 44, 55, 71, 72].  Pre-clinical 251 
models similarly show that bisphosphonates suppress remodeling and increase bone 252 
volume in ovariectomized non-human primates [46, 47, 73], ovariectomized beagles [22, 253 
74], intact minipigs [23], and intact beagles [17, 21, 48, 73, 75-79]. 254 
 255 
In contrast to anti-catabolic agents, PTH has anabolic effects on trabecular bone 256 
formation which are modulated through both bone modeling and remodeling activity 257 
[80].  PTH stimulates trabecular surface modeling [32, 81-83] and affects remodeling by 258 
altering the balance at each remodeling site to favor bone formation [28, 51].  259 
Enhancement of trabecular bone volume and bone remodeling have been shown in 260 
postmenopausal women treated with intermittent PTH [29, 32, 84] although other studies 261 
have shown no significant difference from baseline biopsies in PTH-treated patients for 262 
trabecular formation activity or bone mass [28, 85].  In ovariectomized non-human 263 
primates, multiple skeletal sites (femoral neck, tibia, distal radius, and vertebra) showed 264 
no difference in PTH versus controls for trabecular bone formation rate although bone 265 
formation was stimulated on endocortical surfaces of the mid-radius and mid-femur [86].  266 
Conversely, a separate study showed enhanced bone formation activity on trabecular 267 
bone surfaces of the femoral neck with PTH [49].  Changes with PTH treatment are most 268 
consistent in intact animals, with increases in trabecular/endocortical bone remodeling 269 
having been documented in ewes [87], beagles [51, 88], and rabbits [35, 36].  These pre-270 
clinical models have shown enhancement of trabecular bone formation activity with PTH 271 
results in increased trabecular bone volume by initially producing thicker trabeculae, and 272 
then over time via trabecular tunneling [89], normalizing trabecular thickness and 273 
enhancing trabecular number and connectivity [28, 30, 88, 90]. 274 
 275 
Summary- Trabecular/Endocortical surfaces (Table 1) 276 
Enhanced trabecular/endocortical remodeling at menopause leads to loss of bone mass 277 
and architectural integrity.  Anti-catabolic osteoporosis agents, HRT, SERMs, and 278 
bisphosphonates, suppress remodeling and result in maintenance of trabecular bone 279 
volume and architecture.  By suppressing the deterioration of trabecular bone, these 280 
agents all maintain the biomechanical integrity of skeletal sites containing appreciable 281 
amounts of trabecular bone.  Conversely, anabolic treatment with PTH enhances bone 282 
formation activity on trabecular surfaces which positively affects trabecular bone volume 283 
and architecture.  Based on these effects, both anti-catabolic and anabolic agents have 284 
value for trabecular/endocortical bone with the optimal choice depending on whether the 285 
goal of treatment is slowing deterioration (anti-catabolic agents) or actively enhancing 286 
(anabolic) bone mass and architecture.   287 
 288 
Conclusions 289 
Alterations to bone formation activity on the periosteal, intracortical, and 290 
trabecular/endocortical surfaces imparted by anti-osteoporosis treatments have unique 291 
influences on bone biomechanics.  Although all of the anti-catabolic agents 292 
(estrogen/hormone replacement therapy, SERMs, bisphosphonates) exert positive effects 293 
on the various bone surfaces, bisphosphonates provide a unique biomechanical 294 
combination by allowing normal periosteal expansion while limiting  bone loss on 295 
intracortical and trabecular/endocortical surfaces.  PTH, the only FDA-approved 296 
anabolic, also exerts biomechanically favorable alterations to bone formation on the 297 
various bone surfaces through enhanced activity on trabecular/endocortical surfaces 298 
combined with allowing normal periosteal expansion.  As new agents gain approval for 299 
treatment postmenopausal osteoporosis it will be advantageous to understand how they 300 
each affect the various bone surfaces in order to determine the mechanism(s) through 301 
which they reduce fracture risk.  Equally, if not more important is that this information 302 
will help advance our understanding of surface-specific regulation of bone formation 303 
which ideally can be utilized to design agents that specifically target a particular bone 304 
surface. 305 
306 
 307 
Table 1.  Summary of pharmaceutical effects on surface-specific bone formation* 308 
  
Estrogen/Hormone 
Replacement 
Therapy 
Selective 
Estrogen 
Receptor 
Modulators 
 
 
 
Bisphosphonates 
 
 
Parathyroid 
Hormone 
Periosteal     
Postmenopausal women Decrease -- No effect Increase 
Ovariectomized animals Decrease No effect No effect -- 
Intact animals Decrease Increase No effect Increase 
 
Intracortical 
    
Postmenopausal women Decrease -- No effect / 
Decrease 
 
-- 
Ovariectomized animals Decrease Decrease Decrease Increase 
Intact animals -- No effect Decrease Increase 
 
Endocortical/Trabecular 
    
Postmenopausal women Decrease Decrease Decrease Increase 
Ovariectomized animals Decrease Decrease Decrease Increase 
Intact animals -- Decrease Decrease Increase 
 309 
*In cases where conflicting data exist (see text), the stated effect represents the majority 310 
response.  (--) signifies there are no data available. 311 
312 
Figure Legends 313 
 314 
Fig. 1.  Anti-osteoporosis pharmaceutical agents impart their skeletal effects in part by 315 
altering bone remodeling/modeling on periosteal (B, arrowhead), intracortical (B, arrow), 316 
trabecular (C), and endocortical (D) bone surfaces.  Scale bar = 1 mm (A) or 500 µm (B-317 
D). 318 
 319 
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